PDCD1 and gastric cancer: A meta-analysis compared randomized trials which investigated treatment with or without a PD-1 inhibitor for advanced gastric cancer including provided outcomes in reference to MSI status (KEYNOTE-062, KEYNOTE-061, CHECKMATE-649, JAVELIN Gastric 100); the data were selectively examined according to the role of MSI in response to immunotherapy.